Communicating non-steroidal anti-inflammatory drug risks: Verbal counseling, written medicine information, and patients' risk awareness

Patient Education and Counseling

Volumn 83, Issue 3, 2011, Pages 391-397

  Schmitt, Michael R ^a   Miller, Michael J ^b   Harrison, Donald L ^b   Farmer, Kevin C ^b   Allison, Jeroan J ^c   Cobaugh, Daniel J ^d   Saag, Kenneth G ^e,f  

^a VA Butler Healthcare   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Non steroidal anti inflammatory drugs; Patient counseling; Pharmacists; Physicians; Risk communication; Written medicine information

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; AWARENESS; COMORBIDITY; DOCTOR PATIENT RELATION; DRUG INFORMATION; EDUCATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH INSURANCE; HEALTH LITERACY; HEART INFARCTION; HUMAN; HYPERTENSION; INCOME; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PATIENT COUNSELING; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VERBAL COMMUNICATION;

AGED; ALABAMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMMUNICATION; COUNSELING; CROSS-SECTIONAL STUDIES; DRUG LABELING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PHYSICIANS; QUESTIONNAIRES; RISK; SELF REPORT; SOCIOECONOMIC FACTORS; WRITING;

EID: 79958771534     PISSN: 07383991     EISSN: 18735134     Source Type: Journal    
DOI: 10.1016/j.pec.2010.10.032     Document Type: Article

References (43)

1. Raofi S., Schappert S.M. Medication therapy in ambulatory medical care: United States, 2003-04. Vital Health Stat 2006, 163:1-40.
2. García Rodríguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343:769-772.
3. Johnson A.G. NSAIDs and increased blood pressure: what is the clinical significance?. Drug Safety 1997, 17:277-289.
4. Johnsen S.P., Larsson H., Tarone R.E., McLaughlin J.K., Nørgård B., Friis S., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005, 165:978-984.
5. Gooch K., Culleton B.F., Manns B.J., Zhang J., Alfonso H., Tonelli M., et al. NSAID use and progression of chronic kidney disease. Am J Med 2007, 120:280.e1-280.e7.
6. Singh G., Rosen R.D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998, (Suppl. 51):8-16.
7. Lanas A., Perez-Aisa M.A., Feu F., Ponce J., Saperas E., Santolaria S., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005, 100:1685-1693.
8. National Consumers League. Over-the-counter pain medication study [executive summary]. Available from: 2003 [accessed 14.07.09]. http://www.nclnet.org/otcpain/harrisesummary.htm.
9. Wilcox C.M., Cryer B., Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005, 32:2218-2224.
10. Cham E., Hall L., Ernst A.A., Weiss S.J. Awareness and use of over-the-counter pain medications: a survey of emergency department patients. S Med J 2002, 95:529-535.
11. Cullen G., Kelly E., Murray F.E. Patients' knowledge of adverse reactions to current medications. Brit J Clin Pharmacol 2006, 62:232-236.
12. Ratzan S.C., Parker R.M. Introduction. National Library of Medicine current bibliographies in medicine: health literacy 2000, NLM Pub. No. CBM 2000-1. National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD. C.R. Selden, M. Zorn, S.C. Ratzan, R.M. Parker (Eds.).
13. Persell S., Osborn C., Richard R., Skripkauskas S., Wolf M. Limited health literacy is a barrier to medication reconciliation in ambulatory care. J Gen Intern Med 2007, 22:1523-1526.
14. Davis T.C., Wolf M.S., Bass P.F., Thompson J.A., Tilson H.H., Neuberger M., et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med 2006, 145:887-894.
15. Schillinger D., Bindman A., Wang F., Stewart A., Piette J. Functional health literacy and the quality of physician-patient communication among diabetes patients. Patient Educ Couns 2004, 52:315-323.
16. Koo M.M., Krass I., Aslani P. Patient characteristics influencing evaluation of written medicine information: lessons for patient education. Ann Pharmacother 2005, 39:1434-1440.
17. Wolf M.S., Davis T.C., Shrank W.H., Neuberger M., Parker R.M. A critical review of FDA-approved Medication Guides. Patient Educ Couns 2006, 62:316-322.
18. Kutner M., Greenberg E., Jin Y., Paulsen C. The health literacy of America's adults: results from the 2003 National Assessment of Adult Literacy (NCES 2006-483): U.S. Department of Education 2006, National Center for Education Statistics, Washington, DC.
19. Guidelines for physicians for counseling patients about prescription medications in the ambulatory setting 2004, American Medical Association, Chicago, IL.
20. Schwartzberg J.G., Cowett A., VanGeest J., Wolf M. Communication techniques for patients with low health literacy: a survey of physicians, nurses, and pharmacists. Am J Health Behav 2007, 31:96-104.
21. American Society of Health-System Pharmacists ASHP guidelines on pharmacist-conducted patient education and counseling. Am J Health Syst Ph 1997, 54:431-434.
22. Svarstad B.L., Bultman D.C., Mount J.K. Patient counseling provided in community pharmacies: effects of state regulation, pharmacist age, and busyness. J Am Pharm Assoc 2004, 44:22-29.
23. Flynn E.A., Barker K.N., Berger B.A., Lloyd K.B., Brackett P.D. Dispensing errors and counseling quality in 100 pharmacies. J Am Pharm Assoc 2009, 49:171-180.
24. Medication Guides for prescription drug products. 21 CFR 208.1. Available form: 2008 [accessed 04.09.08]. http://edocket.access.gpo.gov/cfr_2008/aprqtr/21cfr208.1.htm.
25. Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information. Action plan for the provision of useful prescription medicine information. Unpublished report presented to The Honorable Donna E. Shalala, Secretary of the Department of Health and Human Services; 1996.
26. Kimberlin C.L., Winterstein A.G. Expert and consumer evaluation of consumer medication information - 2008 2008, University of Florida.
27. Nicolson D, Knapp P, Raynor DK, Spoor P. Written information about individual medicines for consumers. Cochrane Database Syst Rev 2009. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002104/frame.html.
28. Willems S., De Maesschalck S., Deveugele M., Derese A., De Maeseneer J. Socio-economic status of the patient and doctor-patient communication: does it make a difference?. Patient Educ Couns 2005, 56:139-146.
29. Cobaugh D.J., Angner E., Kiefe C.I., Ray M.N., Lacivita C.L., Weissman N.W., et al. Effect of racial differences on ability to afford prescription medications. Am J Health Syst Ph 2008, 65:2137-2143.
30. Chew L.D., Bradley K.A., Boyko E.J. Brief questions to identify patients with inadequate health literacy. Fam Med 2004, 36:588-594.
31. Chew L.D., Griffin J.M., Partin M.R., Noorbaloochi S., Grill J.P., Snyder A., et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med 2008, 23:561-566.
32. Courtenay B.C., Weidemann C. The effects of a "don't know" response on Palmore's Facts on Aging quizzes. Gerontologist 1985, 25:177-181.
33. Rabe-Hesketh S., Skrondal A. Multilevel modelling of complex survey data. J Roy Stat Soc A 2006, 169:805-827.
34. Stata statistical software (computer program). Version 10 2007, StataCorp LP, College Station, TX.
35. Muthén L.K., Muthén B.O. Mplus user's guide 2007, Muthén & Muthén, Los Angeles, CA. fifth ed.
36. Hox J.J. Multilevel analysis: techniques and applications 2002, Lawrence Erlbaum Associates, Mahwah, NJ.
37. Moore R.A., Derry S., McQuay H.J., Paling J. What do we know about communicating risk: a brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs. Arthritis Res Ther 2008, 10:R20.
38. Tarn D.M., Paterniti D.A., Williams B.R., Cipri C.S., Wenger N.S. Which providers should communicate which critical information about a new medication? Patient, pharmacist, and physician perspectives. J Am Geriatr Soc 2009, 57:462-469.
39. Schommer J.C., Pedersen C.A., Worley M.M., Brown L.M., Hadsall R.S., Ranelli P.L., et al. Provision of risk management and risk assessment information: the role of the pharmacist. Res Social Adm Pharm 2006, 2:458-478.
40. American Society of Health System Pharmacists. Value of pharmacy in patient care. Available form: 2009 [accessed 08.02.10]. http://www.ashp.org/DocLibrary/Policy/PPMI/Value-Outpatient.aspx.
41. Shrank W.H., Avorn J. Educating patients about their medications: the potential and limitations of written drug information. Health Affair 2007, 26:731-740.
42. U.S. Food and Drug Administration. Risk Communication Advisory Committee. Available from: 2009 [accessed 22.05.09]. http://www.fda.gov/oc/advisory/OCRCACACpg.html.
43. Aslani P., Benrimoj S.I., Krass I. Development and evaluation of a training program to foster the use of written drug information in community pharmacies. Part 2: evaluation. Pharm Educ 2007, 7:141-149.